Konference: 2014 50th ASCO Annual Meeting - účast ČR
Kategorie: Gastrointestinální nádory
Číslo abstraktu: 4111^
Autoři: Prof. M.D. Philippe B. Ruszniewski; Prof. M.D. Martyn E. Caplin, FRCP; M.D. Juan W. Valle; Catherine Lombard-Bohas; Graeme John Poston; M.D. Petros Perros, BSc, MBBS, FRCP; Doc. MUDr. Luboš Holubec (jr.), Ph.D., MBA; Prof. M.D. Gianfranco Delle Fave; Denis Michel Smith; Patricia Nicolli; Pascal Maisonobe; Philippe Atlan
Background: Somatostatin analogs can provide CS symptom relief, but associated PROs in clinical practice, in particular patient (pt) treatment satisfaction, are less clear.
Methods: SymNET was a large multinational observational study of PRO after >3 months’ LAN for CS-related diarrhea (NCT01234168). At a routine clinic visit (CV), 273 pts reported their satisfaction with diarrhea control (primary endpoint) on a 5-point Likert scale. Secondary endpoints included health-related quality of life (HRQoL) assessed with EORTC QLQ-C30 and G.I.NET 21 questionnaires completed by pts. HRQoL scores were transformed for some items/scales so that all had a range 0–100. Summary statistics were derived from evaluable data (enrolled population).
Results: 58% (157/273) of pts were >60 yrs, 66% (176/267) had small-bowel primary tumors, and 80% (217/271) had liver metastases. At the CV, median LAN treatment duration was 11 months and 76% (203/268) [95% CI: 70–81%] were satisfied with diarrhea control (primary endpoint). QLQ-C30: problematic symptoms were fatigue, insomnia, diarrhea and, to a lesser extent, pain; in contrast, the majority of pts had no problems with other symptoms, levels of functioning were high, and global QoL only slightly lower (Table). G.I.NET 21: problematic symptoms were disease-related worries, social function, and muscle/bone pain and, to a lesser extent, gastrointestinal and endocrine symptoms; the majority of pts had no problems with other symptoms, including treatment-related effects.
Conclusions: High levels of pt satisfaction with LAN for CS-related diarrhea were generally accompanied by high levels of HRQoL functioning. These data show HRQoL levels that are currently attained in a real-world setting and may help guide future efforts in CS management. Clinical trial information: NCT01234168.
|Functioning scales (higher score=better QoL)||Median score|
|Role; cognitive; social||83|
|General symptoms scale (lower score=better symptoms)|
|Nausea and vomiting||0|
|Specific symptoms scale (lower score = better symptoms)|
|Dyspnea; appetite loss; constipation; financial difficulties||0|
J Clin Oncol 32:5s, 2014 (suppl; abstr 4111^)
Datum přednesení příspěvku: 31. 5. 2014